Tirofiban and emergency coronary surgery

European Journal of Cardio-thoracic Surgery

Volumn 28, Issue 4, 2005, Pages 546-550

  Shanmugam, Ganesh ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Coronary artery bypass grafting; Tirofiban

Indexed keywords

FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; ORBOFIBAN; THROMBOCYTE RECEPTOR; TIROFIBAN;

BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY SURGERY; CORONARY ARTERY THROMBOSIS; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EMERGENCY SURGERY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVIEW; RISK REDUCTION; SURGICAL MORTALITY; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

ACUTE DISEASE; ADMINISTRATION, ORAL; BLOOD PLATELETS; CORONARY ARTERY BYPASS; CORONARY DISEASE; EMERGENCIES; HUMANS; INFUSIONS, INTRAVENOUS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE HEMORRHAGE; THROMBOCYTOPENIA; TYROSINE;

EID: 25144470586     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2005.07.008     Document Type: Review

References (42)

1. C.M. Dyke Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeon's perspective Am Heart J 138 4 Pt 2 1999 307 316
2. R.M. Scarborough, N.S. Kleiman, and D.R. Phillips Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation 100 4 1999 437 444
3. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
4. The EPISTENT Investigators Randomised placebo-controlled and balloon angioplasty- controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade Lancet 352 1998 87 92
5. The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study Lancet 349 1997 1429 1435
6. The IMPACT-II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II Lancet 349 1997 1422 1428
7. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
8. N. Seshadri, P.L. Whitlow, N. Acharya, P. Houghtaling, E.H. Blackstone, and S.G. Ellis Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era Circulation 106 18 2002 2346 2350
9. C.M. Dyke, D. Bhatia, T.J. Lorenz, S.P. Marso, B.E. Tardiff, C. Hogeboom, and R.A. Harrington Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT Ann Thorac Surg 70 3 2000 866 871 [discussion 871-872]
10. D.L. Brown Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment Heart 89 2003 535 537
11. S.D. Brouse, and V.G. Wiesehan Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors Ann Pharmacother 38 11 2004 1783 1788
12. PRISM Study Investigators A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet receptor inhibition in ischemic syndrome management (PRISM) study investigators N Engl J Med 338 21 1998 1498 1505
13. PRISM-PLUS Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators N Engl J Med 338 21 1998 1488 1497
14. J.C. Blankenship Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors Am Heart J 138 4 Pt 2 1999 287 296
15. F. Bizzarri, S. Scolletta, E. Tucci, M. Lucidi, G. Davoli, T. Toscano, E. Neri, L. Muzzi, and G. Frati Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting J Thorac Cardiovasc Surg 122 6 2001 1181 1185
16. H. Dasgupta, J.C. Blankenship, G.C. Wood, C.M. Frey, S.L. Demko, and F.J. Menapace Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis Am Heart J 140 2000 206 211
17. J.E. Tcheng Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment Am Heart J 139 2000 S38 S45
18. E.J. Topol, D.J. Moliterno, H.C. Herrmann, E.R. Powers, C.L. Grines, D.J. Cohen, E.A. Cohen, M. Bertrand, F.J. Neumann, G.W. Stone, P.M. DiBattiste, and L. Demopoulos TARGET investigators. Do Tirofiban and ReoPro give similar efficacy trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 2001 1888 1894
19. J. Llevadot, S.A. Coulter, and R.P. Giuliano A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors J Thromb Thrombolysis 9 2000 175 180
20. P.A. Merlini, M. Rossi, A. Menozzi, S. Buratti, D.M. Brennan, D.J. Moliterno, E.J. Topol, and D. Ardissino Thrombocytopenia caused by Abciximab or Tirofiban and its association with clinical outcome in patients undergoing coronary stenting Circulation 109 18 2004 2203 2206
21. A. Wahba, G. Black, M. Koksch, G. Rothe, J. Preuner, G. Schmitz, and D.E. Birnbaum Cardiopulmonary bypass leads to a preferential loss of activated platelets: a flow cytometric assay of platelet surface antigens Eur J Cardiothorac Surg 10 1996 768 773
22. E.W. Muriithi, P.R. Belcher, J.N. Rao, M.A. Chaudhry, D. Nicol, and D.J. Wheatley The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass J Thorac Cardiovasc Surg 120 2000 538 543
23. E.W. Muriithi, P.R. Belcher, S.P. Day, V.C. Menys, and D.J. Wheatley Heparin induced platelet dysfunction and cardiopulmonary bypass Ann Thorac Surg 69 2000 1827 1832
24. V.C. Menys, P.R. Belcher, M.I. Noble, R.D. Evans, G.E. Drossos, R. Pillai, and S. Westaby Macroaggregation of platelets in plasma, as distinct from microaggregation in whole blood (and plasma), as determined using optical aggregometry and platelet counting respectively, is specifically impaired following cardiopulmonary bypass in man Thromb Haemost 72 1994 511 518
25. M. Genoni, D. Zeller, O. Bertel, M. Maloigne, and M. Turina Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery J Thorac Cardiovasc Surg 122 3 2001 630 632
26. S. Goto, Y. Ikeda, E. Saldivar, and Z.M. Ruggeri Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions J Clin Invest 101 2 1998 479 486
27. 3 binds prothrombin and influences its activation J Biol Chem 272 43 1997 27183 27188
28. M.S. Egbertson, C.T. Chang, M.E. Duggan, R.J. Gould, R.J. Halczenko, G.D. Hartman, W.L. Laswell, J.J. Lynch, R.J. Lynch, and P.D. Manno Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp J Med Chem 37 16 1994 2537 2551
29. S. Harder, U. Klinkhardt, and J.M. Alvarez Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations Clin Pharmacokinet 43 14 2004 963 981
30. K. Umemura Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab Clin Pharmacokinet 41 3 2002 187 195
31. B.S. Coller, D. Lang, and L.E. Scudder Rapid and simple platelet function assay to assess Glycoprotein IIb/IIIa receptor blockade Circulation 95 1997 860 867
32. B.S. Coller Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia Blood 55 1980 169 178
33. B.S. Coller A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet GPIIb/IIIa complex J Clin Invest 76 1985 101 108
34. B.S. Coller, D. Lang, and L.E. Scudder Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade Circulation 95 1997 860 866
35. M.A. Mascelli, S. Worley, N.J. Veriabo, E.T. Lance, S. Mack, T. Schaible, H.F. Weisman, and R.E. Jordan Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy Circulation 96 11 1997 3860 3866
36. J.W. Smith, S.R. Steinhubl, A.M. Lincoff, J.C. Coleman, T.T. Lee, R.S. Hillman, and B.S. Coller Rapid platelet-function assay: an automated and cartridge-based method Circulation 99 5 1999 620 625
37. Y. Suzuki, P. Hillyer, S. Miyamoto, S. Niewiarowski, L. Sun, A.K. Rao, S. Hollenbach, and L.H. Edmunds Jr Integrilin prevents prolonged bleeding times after cardiopulmonary bypass Ann Thorac Surg 66 2 1998 373 381
38. Y. Hiramatsu, N. Gikakis, H.L. Anderson 3rd, J.H. Gorman 3rd, C. Marcinkiewicz, R.J. Gould, S. Niewiarowski, and L.H. Edmunds Jr Tirofiban provides 'platelet anesthesia' during cardiopulmonary bypass in baboons J Thorac Cardiovasc Surg 113 1 1997 182 193
39. J.H. Lemmer Jr Clinical experience in coronary bypass surgery for abciximab-treated patients Ann Thorac Surg 70 2 Suppl 2000 S33 S37
40. W. Lewis, and C.D. Collard Does perioperative antithrombotic therapy increase the likelihood of a postoperative coagulopathy after cardiac surgery? Anesthesiology 92 5 2000 1499 1501
41. C.P. Cannon, C.H. McCabe, S. Borzak, T.D. Henry, M.D. Tischler, H.S. Mueller, R. Feldman, S.T. Palmeri, K. Ault, S.A. Hamilton, J.M. Rothman, W.F. Novotny, and E. Braunwald Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome. Results of the TIMI 12 trial Circulation 97 4 1998 340 349
42. S.R. Steinhubl Antiplatelet agents in cardiology: the choice of therapy Ann Thorac Surg 70 2 Suppl 2000 S3 S8